Atopic Dermatitis
Immunology 6 original drugsMarket Leaders
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q2 2026
Jaktinib Hydrochloride Tablet
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Estimated · fresh NCT05526222
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 68 industry trials with a known mechanism of action.
Janus Kinase Inhibitor
24 trials 6 active 4 sponsors
Interleukin-4 Receptor alpha Antagonist
22 trials 2 active 4 sponsors
Folate Analog Metabolic Inhibitor
1 trials 1 active 1 sponsor
Interleukin-13 Antagonist
12 trials 1 sponsor
Phosphodiesterase 4 Inhibitor
2 trials 2 sponsors
H1 receptor
1 trials 1 sponsor
Calcineurin/FKBP-12
1 trials 1 sponsor
Retinoid
1 trials 1 sponsor
JAK1/JAK2/JAK3/TYK2
1 trials 1 sponsor
Kinase Inhibitor
1 trials 1 sponsor
Interleukin-5 Receptor alpha-directed Cytolytic Antibody
1 trials 1 sponsor
Anti-IgE
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
576 industry-sponsored trials across 215 sponsors
Showing 19 of 19 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Eli Lilly | Lebrikizumab | — | RECRUITING | 2026-04 | NCT07006792 |
| Integrative Skin Science and Research | Roflumilast Cream 0.15% | — | NOT YET RECRUITING | 2027-08 | NCT07560618 |
| Regeneron | dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2024-11-14 | NCT05590585 |
| AbbVie | Upadacitinib | Janus Kinase Inhibitor [EPC] | COMPLETED | 2024-07-11 | NCT05507580 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2024-01-25 | NCT05624112 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2023-12-22 | NCT05680298 |
| Libbs Farmacêutica LTDA | Mometasone Furoate | H1 receptor | COMPLETED | 2023-07-10 | NCT04271007 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2021-10-06 | NCT04033367 |
| Sanofi | Dupilumab SAR231893 | — | COMPLETED | 2021-06-17 | NCT04447417 |
| Pfizer | Crisaborole ointment 2% | — | COMPLETED | 2019-04-12 | NCT03356977 |
| Haus Bioceuticals | HAT1 | — | COMPLETED | 2016-06-26 | NCT03406117 |
| Procter & Gamble Beauty | Investigational OTC Cream | — | COMPLETED | 2016-06 | NCT02732314 |
| Astellas Pharma China, Inc. | tacrolimus | Calcineurin/FKBP-12 | COMPLETED | 2013-11 | NCT01745159 |
| Max Zeller Soehne AG | EPOGAM 1000 | — | COMPLETED | 2010-10 | NCT00878670 |
| Promius Pharma, LLC | Desonide Cream 0.05% | — | COMPLETED | 2009-08 | NCT00828412 |
| Incyte Corporation | ruxolitinib cream | — | TERMINATED | 2025-01-22 | NCT05696392 |
| Pfizer | Crisaborole ointment, 2% | — | TERMINATED | 2020-12-11 | NCT03539601 |
| Regeneron | dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | WITHDRAWN | 2027-12-23 | NCT07187089 |
| LEO Pharma | Cyclosporine A | — | WITHDRAWN | 2020-08 | NCT03710044 |
Showing 100 of 162 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Incyte Corporation | Ruxolitinib | — | RECRUITING | 2026-07-13 | NCT06832618 |
| AbbVie | Upadacitinib 15mg Dose | — | RECRUITING | 2026-08 | NCT06389136 |
| LEO Pharma | Tralokinumab + TCS | — | RECRUITING | 2026-10-20 | NCT06311682 |
| medac GmbH | Methotrexate | Folate Analog Metabolic Inhibitor [EPC] | RECRUITING | 2026-11 | NCT06239311 |
| Beijing InnoCare Pharma Tech Co., Ltd. | ICP-332 Tablets | — | RECRUITING | 2026-11-25 | NCT06775860 |
| Qilu Pharmaceutical Co., Ltd. | 1.5% QLM3003 ointment | — | RECRUITING | 2027-03 | NCT06880276 |
| Pfizer | Abrocitinib | Janus Kinase Inhibitor [EPC] | RECRUITING | 2027-05-02 | NCT06807268 |
| Jiangsu vcare pharmaceutical technology co., LTD | VC005 low dose group | — | RECRUITING | 2027-08-30 | NCT06723080 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1819 Injection | — | RECRUITING | 2027-11 | NCT07309055 |
| Organon and Co | Tapinarof cream, 1% | — | RECRUITING | 2028-01 | NCT07265479 |
| AbbVie | Upadacitinib | Janus Kinase Inhibitor [EPC] | RECRUITING | 2030-07 | NCT06461897 |
| Pfizer | Abrocitinib | Janus Kinase Inhibitor [EPC] | RECRUITING | 2032-02-22 | NCT06807281 |
| Prime Gene Therapeutics Co., Ltd. | PG-011Gel | — | RECRUITING | 2024-11-19 | NCT06587685 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Jaktinib Hydrochloride Tablet | — | ACTIVE NOT RECRUITING | 2026-06 | NCT05526222 |
| Amgen | Rocatinlimab | — | ACTIVE NOT RECRUITING | 2026-06-22 | NCT05882877 |
| Keymed Biosciences Co.Ltd | CM310 | — | ACTIVE NOT RECRUITING | 2026-08-30 | NCT06495229 |
| Galderma R&D | Nemolizumab | — | ACTIVE NOT RECRUITING | 2026-08-31 | NCT03989206 |
| Regeneron | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | ACTIVE NOT RECRUITING | 2026-10-07 | NCT02612454 |
| AbbVie | Upadacitinib | Janus Kinase Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2027-01 | NCT06701331 |
| Almirall, S.A. | Lebrikizumab | — | ACTIVE NOT RECRUITING | 2027-04-25 | NCT06526182 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1819 | — | ACTIVE NOT RECRUITING | 2026-03-31 | NCT06468956 |
| Eli Lilly | Lebrikizumab | — | ACTIVE NOT RECRUITING | 2026-01-14 | NCT05559359 |
| Eli Lilly | Lebrikizumab | — | ACTIVE NOT RECRUITING | 2025-09-25 | NCT06280716 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | TQH2722 injection | — | ACTIVE NOT RECRUITING | 2025-09-11 | NCT06552520 |
| Almirall, S.A. | Lebrikizumab | — | ACTIVE NOT RECRUITING | 2025-06-23 | NCT05990725 |
| Eli Lilly | Baricitinib | Janus Kinase Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2022-04-24 | NCT03952559 |
| AbbVie | Upadacitinib | Janus Kinase Inhibitor [EPC] | ACTIVE NOT RECRUITING | 2021-02-16 | NCT03568318 |
| Otsuka Pharmaceutical Co., Ltd. | OPA-15406 | — | NOT YET RECRUITING | 2026-12 | NCT07173478 |
| Otsuka Pharmaceutical Co., Ltd. | OPA-15406 | — | NOT YET RECRUITING | 2027-02 | NCT07184645 |
| Keymed Biosciences Co.Ltd | Stapokibatrt | — | NOT YET RECRUITING | 2027-02 | NCT07106372 |
| Jiangsu Genscend Biopharmaceutical Co., Ltd | GS101 injection | — | NOT YET RECRUITING | 2027-04 | NCT07386743 |
| Qilu Pharmaceutical Co., Ltd. | QL2108 injection | — | NOT YET RECRUITING | 2027-05 | NCT06884891 |
| Akeso | Placebo | — | NOT YET RECRUITING | 2027-07-10 | NCT06767540 |
| Shanghai Longwood Biopharmaceuticals Co., Ltd. | LW402 | — | NOT YET RECRUITING | 2028-03-31 | NCT07370909 |
| Jiangsu vcare pharmaceutical technology co., LTD | VC005 | — | NOT YET RECRUITING | 2028-05-30 | NCT07592585 |
| Shanghai Mabgeek Biotech.Co.Ltd | MG-K10 Humanized Monoclonal Antibody Injection | — | NOT YET RECRUITING | 2029-01 | NCT07479615 |
| EHL Bio Co., Ltd. | ADSTEM Inj. | — | NOT YET RECRUITING | 2029-06 | NCT07377838 |
| Keymed Biosciences Co.Ltd | Stapokibatrt | — | NOT YET RECRUITING | 2026-05 | NCT06956196 |
| Almirall, S.A. | Lebrikizumab | — | COMPLETED | 2026-04-23 | NCT05916365 |
| Amgen | Rocatinlimab | — | COMPLETED | 2025-07-31 | NCT05633355 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Roflumilast Cream 0.15% | — | COMPLETED | 2025-05-27 | NCT06631170 |
| Incyte Corporation | Ruxolitinib Cream | — | COMPLETED | 2025-05-21 | NCT06238817 |
| LEO Pharma | Tralokinumab | Interleukin-13 Antagonist [EPC] | COMPLETED | 2025-05-05 | NCT05958407 |
| Lynk Pharmaceuticals Co., Ltd | LNK01001 | — | COMPLETED | 2025-04-18 | NCT06277245 |
| Amgen | — | — | COMPLETED | 2025-04-11 | NCT06224192 |
| Amgen | Rocatinlimab | — | COMPLETED | 2025-02-27 | NCT05704738 |
| Keymed Biosciences Co.Ltd | CM310 | — | COMPLETED | 2025-01-23 | NCT06277765 |
| Minghui Pharmaceutical (Hangzhou) Ltd | MH004 Ointment | — | COMPLETED | 2024-12-13 | NCT07185282 |
| Amgen | Rocatinlimab | — | COMPLETED | 2024-11-28 | NCT05398445 |
| Amgen | Rocatinlimab | — | COMPLETED | 2024-09-15 | NCT05724199 |
| Amgen | Rocatinlimab | — | COMPLETED | 2024-08-26 | NCT05899816 |
| Acrotech Biopharma Inc. | Difamilast | — | COMPLETED | 2024-07-31 | NCT05571943 |
| Otsuka Beijing Research Institute | 0.3% OPA-15406 Ointment | — | COMPLETED | 2024-07-21 | NCT05650320 |
| Eli Lilly | Lebrikizumab | — | COMPLETED | 2024-07-19 | NCT04392154 |
| LEO Pharma | Tralokinumab | Interleukin-13 Antagonist [EPC] | COMPLETED | 2024-07-03 | NCT03587805 |
| Otsuka Beijing Research Institute | 1% OPA-15406 Ointment | — | COMPLETED | 2024-06-17 | NCT05667623 |
| Eli Lilly | Lebrikizumab Pen | — | COMPLETED | 2024-06-10 | NCT06444165 |
| Amgen | Rocatinlimab | — | COMPLETED | 2024-06-05 | NCT05651711 |
| Arcutis Biotherapeutics, Inc. | ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | — | COMPLETED | 2024-05-28 | NCT04804605 |
| Incyte Corporation | Ruxolitinib Cream | — | COMPLETED | 2024-05-17 | NCT05456529 |
| Eli Lilly | Lebrikizumab | — | COMPLETED | 2024-05-03 | NCT05372419 |
| AbbVie | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2024-03-19 | NCT05601882 |
| Organon and Co | Tapinarof cream, 1% | — | COMPLETED | 2024-02-29 | NCT05142774 |
| Eli Lilly | Lebrikizumab | — | COMPLETED | 2024-01-11 | NCT05369403 |
| Keymed Biosciences Co.Ltd | CM310 | — | COMPLETED | 2023-10-31 | NCT05265923 |
| Acrotech Biopharma Inc. | Difamilast | — | COMPLETED | 2023-10-27 | NCT05608343 |
| Catalysis SL | — | — | COMPLETED | 2023-09-15 | NCT06361992 |
| AbbVie | Upadacitinib | Janus Kinase Inhibitor [EPC] | COMPLETED | 2023-09-11 | NCT04195698 |
| Pfizer | Abrocitinib 100 mg | — | COMPLETED | 2023-06-09 | NCT05375929 |
| LEO Pharma | Tralokinumab | Interleukin-13 Antagonist [EPC] | COMPLETED | 2023-06-06 | NCT05194540 |
| Arcutis Biotherapeutics, Inc. | Roflumilast Cream 0.05% | — | COMPLETED | 2023-06-01 | NCT04845620 |
| Incyte Corporation | Ruxolitinib | — | COMPLETED | 2023-05-10 | NCT04921969 |
| Organon and Co | tapinarof cream, 1% | — | COMPLETED | 2023-03-30 | NCT05014568 |
| Organon and Co | tapinarof cream, 1% | — | COMPLETED | 2023-02-03 | NCT05032859 |
| Almirall, S.A. | Lebrikizumab | — | COMPLETED | 2023-01-30 | NCT05149313 |
| Otsuka Pharmaceutical Co., Ltd. | OPA-15406 | — | COMPLETED | 2022-12-29 | NCT05372653 |
| Arcutis Biotherapeutics, Inc. | Roflumilast Cream | — | COMPLETED | 2022-09-29 | NCT04773600 |
| Arcutis Biotherapeutics, Inc. | Roflumilast Cream 0.15% | — | COMPLETED | 2022-08-30 | NCT04773587 |
| AbbVie | Upadacitinib | Janus Kinase Inhibitor [EPC] | COMPLETED | 2022-08-19 | NCT03661138 |
| Reistone Biopharma Company Limited | Core Treatment Active Experimental: SHR0302 Dose#1 | — | COMPLETED | 2022-08-12 | NCT04875169 |
| Eli Lilly | Lebrikizumab | — | COMPLETED | 2022-08-03 | NCT04626297 |
| Eli Lilly | Lebrikizumab | — | COMPLETED | 2022-07-31 | NCT04760314 |
| Regeneron | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2022-06-27 | NCT01949311 |
| Eli Lilly | Lebrikizumab | — | COMPLETED | 2022-04-20 | NCT04250350 |
| Galderma R&D | Nemolizumab | — | COMPLETED | 2022-02-23 | NCT03989349 |
| Pfizer | Crisaborole 2% | — | COMPLETED | 2022-01-19 | NCT04040192 |
| Galderma R&D | Nemolizumab | — | COMPLETED | 2021-12-29 | NCT03985943 |
| Sanofi | Dupilumab SAR231893 | — | COMPLETED | 2021-12-14 | NCT04678882 |
| Pfizer | Crisaborole Ointment | — | COMPLETED | 2021-09-08 | NCT04360187 |
| Eli Lilly | Lebrikizumab | — | COMPLETED | 2021-08-11 | NCT04250337 |
| Pfizer | Abrocitinib 200 mg | — | COMPLETED | 2021-07-13 | NCT04345367 |
| Eli Lilly | Lebrikizumab | — | COMPLETED | 2021-07-12 | NCT04178967 |
| LEO Pharma | Tralokinumab | Interleukin-13 Antagonist [EPC] | COMPLETED | 2021-07-06 | NCT04587453 |
| Eli Lilly | Lebrikizumab | — | COMPLETED | 2021-06-21 | NCT04146363 |
| AbbVie | Upadacitinib | Janus Kinase Inhibitor [EPC] | COMPLETED | 2021-03-11 | NCT03607422 |
| AbbVie | Upadacitinib | Janus Kinase Inhibitor [EPC] | COMPLETED | 2021-01-06 | NCT03569293 |
| Otsuka Pharmaceutical Co., Ltd. | 0.3% OPA-15406 ointment | — | COMPLETED | 2020-11-11 | NCT03961529 |
| Eli Lilly | Baricitinib | Janus Kinase Inhibitor [EPC] | COMPLETED | 2020-09-21 | NCT03334435 |
| Pfizer | PF-04965842 100 mg | — | COMPLETED | 2020-09-02 | NCT03627767 |
| AbbVie | Upadacitinib | Janus Kinase Inhibitor [EPC] | COMPLETED | 2020-08-27 | NCT03738397 |
Showing 100 of 280 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Oneness Biotech Co., Ltd. | FB825 | — | RECRUITING | 2026-06-30 | NCT06397911 |
| Turn Therapeutics | — | — | RECRUITING | 2026-07-10 | NCT07355075 |
| Keymed Biosciences Co.Ltd | CM512 | — | RECRUITING | 2026-07-18 | NCT06947980 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1905 Injection | — | RECRUITING | 2026-09 | NCT07211542 |
| Pfizer | PF-07275315 | — | RECRUITING | 2026-10-19 | NCT05995964 |
| Inmagene LLC | IMG-007 | — | RECRUITING | 2026-11 | NCT07037901 |
| Enveda Therapeutics | ENV-294 | — | RECRUITING | 2026-12 | NCT07298395 |
| AbbVie | Lutikizumab | — | RECRUITING | 2027-02 | NCT06524635 |
| Bluefin Biomedicine, Inc. | BFB759 | — | RECRUITING | 2027-02-28 | NCT07105488 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI3002 | — | RECRUITING | 2027-03-23 | NCT07399067 |
| SinoMab BioScience Ltd | SM17 for subcutaneous injection | — | RECRUITING | 2027-04-25 | NCT07445919 |
| UCB Biopharma SRL | Galvokimig | — | RECRUITING | 2027-05-17 | NCT07277660 |
| Kymera Therapeutics, Inc. | KT-621 | — | RECRUITING | 2027-06 | NCT07217015 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1819 Injection | — | RECRUITING | 2027-06 | NCT07321951 |
| Corvus Pharmaceuticals, Inc. | Soquelitinib | — | RECRUITING | 2027-06 | NCT07441395 |
| Innovent Biologics (Suzhou) Co. Ltd. | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | RECRUITING | 2027-06-30 | NCT07330934 |
| Apollo Therapeutics Ltd | Camoteskimab | — | RECRUITING | 2027-10-31 | NCT07599813 |
| Keymed Biosciences Co.Ltd | CM512 | — | RECRUITING | 2027-12 | NCT07230483 |
| Chengdu Zenitar Biomedical Technology Co., Ltd | The high-dose group of ZL-82 tablets | — | RECRUITING | 2027-12-30 | NCT07193589 |
| Novartis | GHZ339 | — | RECRUITING | 2028-11-27 | NCT06947993 |
| Apogee Therapeutics, Inc. | APG777 | — | RECRUITING | 2029-12 | NCT07003425 |
| Roche | Afimkibart | — | RECRUITING | 2033-03-01 | NCT07223697 |
| Alphyn Biologics | zabalafin | — | RECRUITING | 2025-10-30 | NCT06855745 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1819 injection | — | RECRUITING | 2025-09 | NCT06713499 |
| Shanghai Mabgeek Biotech.Co.Ltd | MG-K10 | — | RECRUITING | 2025-05 | NCT06765005 |
| Shaperon | HY209GEL Active | — | ACTIVE NOT RECRUITING | 2026-06-30 | NCT06024499 |
| Roche | Afimkibart | — | ACTIVE NOT RECRUITING | 2026-07-22 | NCT06863961 |
| Aclaris Therapeutics, Inc. | ATI-045 | — | ACTIVE NOT RECRUITING | 2026-08 | NCT07011706 |
| Triveni Bio | TRIV-509 | — | ACTIVE NOT RECRUITING | 2026-10 | NCT07167758 |
| Apogee Therapeutics, Inc. | APG777 | — | ACTIVE NOT RECRUITING | 2026-11 | NCT06395948 |
| AbbVie | Lutikizumab | — | ACTIVE NOT RECRUITING | 2027-05 | NCT06718101 |
| Novartis | GIA632 | — | ACTIVE NOT RECRUITING | 2027-05-17 | NCT07220577 |
| Pfizer | PF-08049820 | — | ACTIVE NOT RECRUITING | 2027-08-23 | NCT07216027 |
| Celldex Therapeutics | Barzolvolimab | — | ACTIVE NOT RECRUITING | 2026-05 | NCT06727552 |
| Xizang Haisco Pharmaceutical Co., Ltd | HSK44459 | — | ACTIVE NOT RECRUITING | 2026-01-20 | NCT06996912 |
| Nektar Therapeutics | Rezpegaldesleukin | — | ACTIVE NOT RECRUITING | 2025-05-06 | NCT06136741 |
| Tavotek Biotherapeutics | TAVO101 | — | ACTIVE NOT RECRUITING | 2025-03-15 | NCT06176040 |
| Q32 Bio Inc. | ADX-914 | — | ACTIVE NOT RECRUITING | 2024-12 | NCT05509023 |
| EHL Bio Co., Ltd. | ADSTEM Inj. | — | ACTIVE NOT RECRUITING | 2023-01-26 | NCT04137562 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | SIM0278 injection | — | NOT YET RECRUITING | 2026-08-15 | NCT07175233 |
| HK inno.N Corporation | IN-115314 Ointment 1% | — | NOT YET RECRUITING | 2026-09-30 | NCT07073677 |
| Enzychem Lifesciences Corporation | EC-18 | — | NOT YET RECRUITING | 2026-10 | NCT06487000 |
| Dermavon Holdings Limited | CMS-D001 50mg | — | NOT YET RECRUITING | 2027-01-31 | NCT07465120 |
| Jiangsu vcare pharmaceutical technology co., LTD | VC005 group | — | NOT YET RECRUITING | 2027-02-22 | NCT07598383 |
| Shanghai Mabgeek Biotech.Co.Ltd | MG-K10 placebo | — | NOT YET RECRUITING | 2027-07-16 | NCT07103174 |
| Qilu Pharmaceutical Co., Ltd. | QLS12010 | — | NOT YET RECRUITING | 2027-09 | NCT07344051 |
| Akeso | AK139 | — | NOT YET RECRUITING | 2027-11 | NCT07502222 |
| Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | LT-002-158 tablets | — | NOT YET RECRUITING | 2025-10-30 | NCT06931990 |
| Zhejiang Kanova Biopharmaceutical Co., LTD | XKH001 Injection | — | NOT YET RECRUITING | 2025-10-01 | NCT07054736 |
| Akeso | AK120 | — | NOT YET RECRUITING | 2025-06-30 | NCT06756126 |
| Reistone Biopharma Company Limited | RSS0393 ointment | — | COMPLETED | 2026-04-10 | NCT07158151 |
| Arcutis Biotherapeutics, Inc. | ARQ-151 cream 0.05% | — | COMPLETED | 2025-12-04 | NCT06998056 |
| Hangzhou Yirui Pharmaceutical Technology Co., Ltd | YR001 ointment | — | COMPLETED | 2025-11-20 | NCT06309355 |
| Evommune, Inc. | EVO301 | — | COMPLETED | 2025-11-17 | NCT06723405 |
| Jiangsu vcare pharmaceutical technology co., LTD | VC005 groups | — | COMPLETED | 2025-10-31 | NCT06891040 |
| CAGE Bio Inc. | CGB-500 with 0.5% tofacitinib | — | COMPLETED | 2025-08-30 | NCT06810050 |
| Akeso | AK120 300mg Q2W (JAK inhibitor users need to double the initial dose) | — | COMPLETED | 2025-07-31 | NCT06700499 |
| CAGE Bio Inc. | CGB-500 Ointment with 1% tofacitinib | — | COMPLETED | 2025-07-30 | NCT06923228 |
| Lynk Pharmaceuticals Co., Ltd | LNK01004 ointment 0.3% | — | COMPLETED | 2025-07-24 | NCT07071610 |
| UCB Biopharma SRL | UCB1381 | — | COMPLETED | 2025-07-17 | NCT05277571 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | SHR-1819 injection | — | COMPLETED | 2025-06-05 | NCT06012812 |
| Galderma R&D | Nemolizumab | — | COMPLETED | 2025-04-28 | NCT04921345 |
| Apollo Therapeutics Ltd | Camoteskimab | — | COMPLETED | 2025-03-26 | NCT06436183 |
| Aclaris Therapeutics, Inc. | ATI-2138 | — | COMPLETED | 2025-03-13 | NCT06585202 |
| Technoderma Medicines Inc. | TDM-180935 topical ointment 1.0% | — | COMPLETED | 2025-03-08 | NCT06363461 |
| Xantho Biotechnology Co., LTD | GM-XANTHO onitment | — | COMPLETED | 2025-01-22 | NCT04369846 |
| LEO Pharma | LEO 138559 | — | COMPLETED | 2024-12-11 | NCT05923099 |
| Siolta Therapeutics, Inc. | STMC-103H | — | COMPLETED | 2024-11-26 | NCT05003804 |
| Akeso | AK120 | — | COMPLETED | 2024-11-13 | NCT06092762 |
| Shanghai Longwood Biopharmaceuticals Co., Ltd. | LW402 | — | COMPLETED | 2024-09-25 | NCT07186387 |
| Biosion, Inc. | BSI-045B | — | COMPLETED | 2024-09-18 | NCT05932654 |
| Qilu Pharmaceutical Co., Ltd. | 1.5% QLM3003 | — | COMPLETED | 2024-09-02 | NCT06058000 |
| Escient Pharmaceuticals, Inc | Oral EP262 | — | COMPLETED | 2024-07-31 | NCT06144424 |
| Keymed Biosciences Co.Ltd | CM310 | — | COMPLETED | 2024-07-18 | NCT05715320 |
| Jiangsu vcare pharmaceutical technology co., LTD | VC005 tablets | — | COMPLETED | 2024-07-09 | NCT05997927 |
| Keymed Biosciences Co.Ltd | CM310 | — | COMPLETED | 2024-07-04 | NCT06162507 |
| Akeso | AK120 | — | COMPLETED | 2024-06-21 | NCT06035354 |
| UCB Biopharma SRL | UCB9741 | — | COMPLETED | 2024-04-23 | NCT04643457 |
| Ganzhou Hemay Pharmaceutical Co., Ltd | Hemay005 | — | COMPLETED | 2024-01-24 | NCT05769946 |
| UNION therapeutics | Orismilast modified release tablets | — | COMPLETED | 2024-01-23 | NCT05469464 |
| Bayer | Zabedosertib (BAY1834845) | — | COMPLETED | 2024-01-03 | NCT05656911 |
| Amytrx Therapeutics, Inc. | 1.1% w/w AMTX-100 CF-part1 | — | COMPLETED | 2023-12-19 | NCT04313400 |
| Aldeyra Therapeutics, Inc. | ADX-629 (Open-label) | — | COMPLETED | 2023-11-21 | NCT05717920 |
| Aclaris Therapeutics, Inc. | ATI-1777 2.0% w/w | — | COMPLETED | 2023-10-26 | NCT05432596 |
| LEO Pharma | Tralokinumab | Interleukin-13 Antagonist [EPC] | COMPLETED | 2023-10-20 | NCT05388760 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | SHR-1819 | — | COMPLETED | 2023-09-15 | NCT05549947 |
| Incyte Corporation | Ruxolitinib cream | — | COMPLETED | 2023-08-03 | NCT05127421 |
| Pfizer | PF-07038124 ointment 0.01% | — | COMPLETED | 2023-07-31 | NCT05375955 |
| Keymed Biosciences Co.Ltd | CM310 | — | COMPLETED | 2023-07-28 | NCT05579925 |
| Evommune, Inc. | EVO101 | — | COMPLETED | 2023-07-27 | NCT05579899 |
| JW Pharmaceutical | LEO 152020 tablet | — | COMPLETED | 2023-07-20 | NCT05117060 |
| CAGE Bio Inc. | Tofacitinib Citrate | JAK1/JAK2/JAK3/TYK2 | COMPLETED | 2023-06-30 | NCT05487963 |
| Sanofi | Rilzabrutinib | Kinase Inhibitor [EPC] | COMPLETED | 2023-06-23 | NCT05018806 |
| Lynk Pharmaceuticals Co., Ltd | LNK01001 Dose A | — | COMPLETED | 2023-06-14 | NCT06085521 |
| LEO Pharma | LEO 138559 | — | COMPLETED | 2023-06-07 | NCT05470114 |
| Galderma R&D | Nemolizumab | — | COMPLETED | 2023-06-07 | NCT04562116 |
| Kymab Limited | Amlitelimab | — | COMPLETED | 2023-04-26 | NCT05131477 |
| Evelo Biosciences, Inc. | EDP1815 | — | COMPLETED | 2023-03-09 | NCT05121480 |
| Keymed Biosciences Co.Ltd | CM310 | — | COMPLETED | 2023-02-03 | NCT04893707 |
| BenevolentAI Bio | BEN2293 (0.25% or 1.0% w/w) or matching placebo | — | COMPLETED | 2023-01-12 | NCT04737304 |
Showing 100 of 115 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Bambusa Therapeutics | BBT001 | — | RECRUITING | 2026-08-21 | NCT06808477 |
| Sitryx Therapeutics Ltd | SYX-5219 Oral Capsule | — | RECRUITING | 2026-08-30 | NCT07558668 |
| Bambusa Therapeutics | BBT001 | — | RECRUITING | 2026-08-31 | NCT07239947 |
| Jiangsu Genscend Biopharmaceutical Co., Ltd | GS101 injection | — | RECRUITING | 2026-09 | NCT07411755 |
| Good Molecules, LLC | OTC Drug for Atopic Dermatitis in Cream form | — | RECRUITING | 2026-09-25 | NCT07146971 |
| Attovia Therapeutics Inc | ATTO-3712 | — | RECRUITING | 2026-10 | NCT07205081 |
| Chong Kun Dang Pharmaceutical | CKD-706 | — | RECRUITING | 2026-11-16 | NCT07358156 |
| Pfizer | PF-07832837 | — | RECRUITING | 2027-06-02 | NCT06564389 |
| TRex Bio, Inc. | TRB-061 | — | RECRUITING | 2027-09-02 | NCT06934252 |
| Zai Lab (Shanghai) Co., Ltd. | ZL-1503 | — | RECRUITING | 2027-12-28 | NCT07235384 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SKB575 Injection/SKB575 Placebo | — | RECRUITING | 2027-12-31 | NCT07488065 |
| Arcutis Biotherapeutics, Inc. | ARQ-234 | — | RECRUITING | 2028-04 | NCT07453602 |
| BeiGene | BGB-45035 | — | RECRUITING | 2026-05-23 | NCT06342713 |
| Brexogen Inc. | BxC-I17e (primed iMSC derived Extracellular vesicles(EV)) | — | RECRUITING | 2026-03-31 | NCT06055361 |
| LAPIX Therapeutics Inc. | LPX-TI641 | — | RECRUITING | 2026-01-15 | NCT06982352 |
| Shanghai Qilu Pharmaceutical Research and Development Center LTD | QLS12010 | — | RECRUITING | 2025-12 | NCT06946641 |
| Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | LT-002-158/Placebo oral tablet(s) | — | RECRUITING | 2025-03-31 | NCT06082323 |
| Generate Biomedicines | GB-7624 | — | ACTIVE NOT RECRUITING | 2026-08-30 | NCT06920693 |
| Apogee Therapeutics, Inc. | APG777 | — | ACTIVE NOT RECRUITING | 2026-12 | NCT07027527 |
| Attovia Therapeutics Inc | ATTO-1310 | — | ACTIVE NOT RECRUITING | 2026-05 | NCT06787586 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1819 Injection | — | ACTIVE NOT RECRUITING | 2026-04 | NCT07264335 |
| Pfizer | PF-08049820 | — | ACTIVE NOT RECRUITING | 2025-12-15 | NCT07190430 |
| Jiangsu vcare pharmaceutical technology co., LTD | VC005 Tablets | — | NOT YET RECRUITING | 2026-10-30 | NCT07533851 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI3033 | — | NOT YET RECRUITING | 2027-02-10 | NCT07549984 |
| Helixon Biotechnology (Suzhou) Co., Ltd | HXN5003 | — | NOT YET RECRUITING | 2027-03-18 | NCT07549750 |
| Seismic Therapeutic AU Pty Ltd | S-4321 | — | NOT YET RECRUITING | 2027-06 | NCT07455578 |
| Regeneron | REGN20423 | — | NOT YET RECRUITING | 2028-06-09 | NCT07527923 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | new formulations of 611 | — | NOT YET RECRUITING | 2026-01 | NCT07042113 |
| Jiangsu vcare pharmaceutical technology co., LTD | VC005 | — | COMPLETED | 2026-02-06 | NCT07329101 |
| SinoMab BioScience Ltd | SM17 | — | COMPLETED | 2026-02-03 | NCT07466940 |
| Corvus Pharmaceuticals, Inc. | Soquelitinib | — | COMPLETED | 2026-01-28 | NCT06345404 |
| Enveda Therapeutics | ENV-294 Capsule | — | COMPLETED | 2026-01-13 | NCT07336940 |
| Kymera Therapeutics, Inc. | KT-621 | — | COMPLETED | 2025-11-10 | NCT06945458 |
| Pfizer | PF-08049820 MR1 | — | COMPLETED | 2025-10-04 | NCT07172321 |
| Keymed Biosciences Co.Ltd | CM512 | — | COMPLETED | 2025-08-26 | NCT06553209 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI356 for MAD | — | COMPLETED | 2025-08-20 | NCT06193434 |
| Jiangsu vcare pharmaceutical technology co., LTD | [14C]VC005 | — | COMPLETED | 2025-06-03 | NCT06974292 |
| Amgen | Rocatinlimab | — | COMPLETED | 2025-05-03 | NCT06438263 |
| SinoMab BioScience Ltd | SM17 for injection | — | COMPLETED | 2025-03-24 | NCT07103369 |
| Qilu Pharmaceutical Co., Ltd. | QL2108 injection | — | COMPLETED | 2024-11-15 | NCT06614907 |
| Sun Pharmaceutical Industries, Inc. | Ruxolitinib Topical Cream 1.5% | — | COMPLETED | 2024-09-23 | NCT06673654 |
| Amgen | Rocatinlimab vial injection | — | COMPLETED | 2024-08-30 | NCT06268860 |
| AbbVie | Upadacitinib (ABT-494) | — | COMPLETED | 2024-08-29 | NCT03646604 |
| Lynk Pharmaceuticals Co., Ltd | LNK01004 ointment 0.3% | — | COMPLETED | 2024-06-18 | NCT06553287 |
| Amgen | Rocatinlimab | — | COMPLETED | 2024-05-27 | NCT06214481 |
| Jiangsu vcare pharmaceutical technology co., LTD | VC005 | — | COMPLETED | 2024-05-23 | NCT06009094 |
| selectION Therapeutics GmbH | si-544 | — | COMPLETED | 2023-11-01 | NCT05383378 |
| Hangzhou Highlightll Pharmaceutical Co., Ltd | TLL-018 extended-release tablet | — | COMPLETED | 2023-08-28 | NCT05945810 |
| Hangzhou Yirui Pharmaceutical Technology Co., Ltd | YR001 Dose A on low body surface area | — | COMPLETED | 2023-08-14 | NCT05718921 |
| Incyte Corporation | Ruxolitinib cream | — | COMPLETED | 2023-08-07 | NCT05034822 |
| Qilu Pharmaceutical Co., Ltd. | QLM3003 | — | COMPLETED | 2023-08-05 | NCT05932888 |
| Arcutis Biotherapeutics, Inc. | ARQ-151 cream 0.15% | — | COMPLETED | 2023-05-02 | NCT04156191 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | Experimental drug 9MW1911 | — | COMPLETED | 2023-03-06 | NCT05803902 |
| Biosion, Inc. | BSI-045B | — | COMPLETED | 2023-02-15 | NCT05114889 |
| Pfizer | PF-07242813 | — | COMPLETED | 2022-12-27 | NCT04668066 |
| Kymera Therapeutics, Inc. | KT-474 | — | COMPLETED | 2022-10-20 | NCT04772885 |
| OrchestratePharma GmbH | Fexofenadine Hydrochloride Topical Lotion 1% (OP2101) | — | COMPLETED | 2022-10-16 | NCT05461456 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | 9MW1911 Injection | — | COMPLETED | 2022-07-03 | NCT05170243 |
| LEO Pharma | LEO 138559 | — | COMPLETED | 2022-06-28 | NCT05099133 |
| Evelo Biosciences, Inc. | EDP1867 | — | COMPLETED | 2022-02-28 | NCT04927195 |
| NovaCell Technology Inc. | NCP112 | — | COMPLETED | 2021-11-20 | NCT05638165 |
| LEO Pharma | delgocitinib | Janus Kinase Inhibitor [EPC] | COMPLETED | 2021-10-29 | NCT03826901 |
| Akesobio Australia Pty Ltd | AK120 or placebo- Part 1- Cohort 1 | — | COMPLETED | 2021-10-29 | NCT04256174 |
| Evelo Biosciences, Inc. | EDP1815 | — | COMPLETED | 2021-10-29 | NCT03733353 |
| Novartis | CEE321 | — | COMPLETED | 2021-05-16 | NCT04612062 |
| RAPT Therapeutics, Inc. | RPT193 | — | COMPLETED | 2021-04-26 | NCT04271514 |
| Pfizer | PF-06817024 | — | COMPLETED | 2021-03-09 | NCT02743871 |
| LEO Pharma | LEO 138559 | — | COMPLETED | 2021-03-02 | NCT03514511 |
| Incyte Corporation | Ruxolitinib phosphate cream | — | COMPLETED | 2020-10-07 | NCT03257644 |
| LEO Pharma | Tralokinumab | Interleukin-13 Antagonist [EPC] | COMPLETED | 2020-03-16 | NCT03556592 |
| Novartis | LOU064 | — | COMPLETED | 2020-01-27 | NCT03918980 |
| Evelo Biosciences, Inc. | Placebo oral capsule | — | COMPLETED | 2020-01-03 | NCT03542994 |
| Incyte Corporation | Ruxolitinib cream | — | COMPLETED | 2019-12-26 | NCT03920852 |
| KoBioLabs | KBL697 | — | COMPLETED | 2019-12-23 | NCT04056130 |
| AOBiome LLC | Experimental: B244 | — | COMPLETED | 2019-05-18 | NCT03775434 |
| Shaperon | HY209 | — | COMPLETED | 2019-03-21 | NCT03492398 |
| Novan, Inc. | SB414 2% | — | COMPLETED | 2018-05-11 | NCT03431610 |
| EHL Bio Co., Ltd. | ADSTEM Inj. (Adult human mesenchymal stem cells) | — | COMPLETED | 2017-12 | NCT02888704 |
| Pfizer | Crisaborole ointment 2% | — | COMPLETED | 2017-11-27 | NCT03260595 |
| Johnson & Johnson | Part 1: CNTO 7160 | — | COMPLETED | 2017-03-16 | NCT02345928 |
| Regeneron | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2016-07 | NCT02647086 |
| Reckitt Benckiser Healthcare (UK) Limited | — | — | COMPLETED | 2016-04 | NCT02620293 |
| LEO Pharma | LEO 32731 cream | — | COMPLETED | 2016-03 | NCT02496546 |
| Xencor, Inc. | XmAb7195 | — | COMPLETED | 2015-09-21 | NCT02148744 |
| LEO Pharma | Pimecrolimus cream | — | COMPLETED | 2015-07 | NCT02376049 |
| Bristol-Myers Squibb | BMS-981164 | — | COMPLETED | 2015-04 | NCT01614756 |
| Otsuka Pharmaceutical Co., Ltd. | 0.3% OPA-15406 Ointment | — | COMPLETED | 2015-02 | NCT02334787 |
| LEO Pharma | LEO 39652 cream | — | COMPLETED | 2014-12 | NCT02219633 |
| LEO Pharma | LEO 39652 cream | — | COMPLETED | 2014-11 | NCT01850849 |
| LEO Pharma | pimecrolimus 10 mg/g cream | — | COMPLETED | 2014-09 | NCT02103725 |
| Novartis | BPR277 ointment (controlled application) | — | COMPLETED | 2014-02 | NCT01428297 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | OPA-15406 | — | COMPLETED | 2013-12 | NCT01702181 |
| MedImmune LLC | Omalizumab | Anti-IgE [EPC] | COMPLETED | 2013-06 | NCT01544348 |
| LEO Pharma | LEO 29102 | — | COMPLETED | 2012-11 | NCT01423656 |
| Regeneron | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2012-03-31 | NCT01385657 |
| Amgen | Tezepelumab | — | COMPLETED | 2011-01-05 | NCT00757042 |
| LEO Pharma | LEO 29102 cream | — | COMPLETED | 2010-05 | NCT01005823 |
| Sun Pharmaceutical Industries, Inc. | Tacrolimus 0.1% manufactured by Taro | — | COMPLETED | 2010-02 | NCT00833079 |
| LEO Pharma | LEO 29102 cream | — | COMPLETED | 2009-10 | NCT00958516 |
| LEO Pharma | LEO 29102 | — | COMPLETED | 2009-06 | NCT00891709 |
Novel Drugs by Company (New molecular entities)
Reformulations (15 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
RINVOQ LQ
AbbVie
T3 2024
ZORYVE
ARCUTIS
T3 2022
OPZELURA
INCYTE CORP
T10 2021
DEXYCU KIT
EYEPOINT PHARMS
T5 2018
EUCRISA
ANACOR PHARMS INC
T1 2016
ORAPRED ODT
ADVANZ PHARMA
T3 2006
ELIDEL
BAUSCH
T1 2001
LOCOID LIPOCREAM
PRECISION DERMAT
T3 1997
ZONALON
Viatris
T3 1994
PEDIAPRED
PAI HOLDINGS
T3 1986
CELESTONE SOLUSPAN
Merck
T1 1965
KENALOG-40
APOTHECON
T5 1965
DEPO-MEDROL
Pfizer
T2 1959
SOLU-MEDROL
PHARMACIA AND UPJOHN
T2 1959
SOLU-CORTEF
PHARMACIA AND UPJOHN
T2 1955
Generic Drugs (6 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs